Researchers have found a way to evaluate the quality of kidneys before transplantation that could help increase the number of usable donor kidneys.
The study has been published in the ‘Optics Express Journal’.
“Today, the lack of methods for precisely measuring donor kidney injury and predicting transplant outcome leads to high discard rates and recipient complications in clinical practice,” said research team leader Mingxing Sui from Changhai Hospital of Shanghai in China.
“We want to solve this problem by developing a new system that can noninvasively provide an objective measure of donor kidney quality,” Sui added.
Sui and colleagues from the University of Shanghai for Science and Technology in China reported the first use of surface-enhanced Raman scattering (SERS) for simultaneous, ultrasensitive detection of two important kidney injury biomarkers. They also described how they made SERS spectroscopy more practical for clinical use.
“This highly sensitive SERS-based multiplexing technique can rapidly capture subtle changes in the biomarker expression levels associated with donor kidney injury. This paves the way for objectively assessing the quality of donor kidneys in clinical practice,” Sui said.
When a person donates a kidney after death, the process often involves taking a biopsy to assess the health of the kidney that will be donated. This step is not only invasive and time-consuming but might also be causing too many donor kidneys to be disqualified. Research has shown that biopsy findings don’t always predict how well a kidney will function once transplanted.
Recently, researchers have identified secretory leukocyte peptidase inhibitor (SLPI) and interleukin 18 (IL-18) as biomarkers present in a person’s blood and urine that can be used to objectively evaluate kidney injury. Although various analysis methods have been explored to detect these biomarkers, they have all come up short due to limited sensitivity, lack of multiplexing, complicated sample preparation, or high cost.
Sui’s research team wanted to find out if SERS could provide a better way to detect these biomarkers. This relatively new vibrational spectroscopy technique offered single-molecule sensitivity was easy and fast to perform and allowed multiple biomarkers to be detected using a single measurement.
It works by using nanostructures to enhance the Raman scattering that occurs when molecules are adsorbed onto a metal surface. This scattering forms a type of spectral fingerprint that is unique for each molecule.
However, moving SERS out of the lab and into the clinic required finding ways to further improve its sensitivity, reproducibility, and simplicity. The researchers achieved this by developing a new hybrid SERS substrate that combined gold nanoparticles with a new 2D nanomaterial known as black phosphorus.
The new nanosheets offer several advantages, including a high affinity toward the biomolecules, which boosts the sensitivity. They also eliminate the need for labels, making measurements easier to perform.
“Although this work is still at an early stage, we think SERS could be used in clinical practice in the foreseeable future,” Sui said.
“By collecting the donor urine or serum, the expression level of kidney injury biomarkers could be noninvasively, rapidly and reproducibly measured, which is highly preferable in clinical practice in contrast to biopsies of kidneys,” Sui added.
The researchers are now working to identify more biomarkers that could help to more accurately assess donor kidney quality. They are also developing machine learning algorithms to improve the interpretation of spectral fingerprints.